PL2037879T3 - Kompozycje soli glikopironiowej do inhalacji - Google Patents
Kompozycje soli glikopironiowej do inhalacjiInfo
- Publication number
- PL2037879T3 PL2037879T3 PL07764925T PL07764925T PL2037879T3 PL 2037879 T3 PL2037879 T3 PL 2037879T3 PL 07764925 T PL07764925 T PL 07764925T PL 07764925 T PL07764925 T PL 07764925T PL 2037879 T3 PL2037879 T3 PL 2037879T3
- Authority
- PL
- Poland
- Prior art keywords
- inhalation
- compositions
- glycopyrronium salt
- glycopyrronium
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0613161.9A GB0613161D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
EP07764925.9A EP2037879B1 (en) | 2006-06-30 | 2007-06-28 | Compositions of glycopyrronium salt for inhalation |
PCT/EP2007/005744 WO2008000482A1 (en) | 2006-06-30 | 2007-06-28 | Compositions of glycopyrronium salt for inhalation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2037879T3 true PL2037879T3 (pl) | 2013-09-30 |
Family
ID=36888514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07764925T PL2037879T3 (pl) | 2006-06-30 | 2007-06-28 | Kompozycje soli glikopironiowej do inhalacji |
Country Status (15)
Country | Link |
---|---|
US (4) | US20090209502A1 (pl) |
EP (1) | EP2037879B1 (pl) |
JP (1) | JP5266213B2 (pl) |
KR (1) | KR101400579B1 (pl) |
CN (1) | CN101484134B (pl) |
AU (1) | AU2007264000B2 (pl) |
BR (1) | BRPI0713777B8 (pl) |
CA (1) | CA2655381C (pl) |
ES (1) | ES2424754T3 (pl) |
GB (1) | GB0613161D0 (pl) |
MX (1) | MX2008016356A (pl) |
PL (1) | PL2037879T3 (pl) |
PT (1) | PT2037879E (pl) |
RU (1) | RU2453302C2 (pl) |
WO (1) | WO2008000482A1 (pl) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
CA2479751C (en) | 2002-03-20 | 2008-06-03 | Trent Poole | Inhalation apparatus |
BRPI0514263B8 (pt) | 2004-08-20 | 2021-05-25 | Mannkind Corp | método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida |
DK2314298T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Microparticles comprising diketopiperazinsalte for drug delivery |
US7803404B2 (en) | 2005-09-14 | 2010-09-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
BRPI0707991B8 (pt) | 2006-02-22 | 2021-05-25 | Mannkind Corp | métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco |
WO2009074662A2 (en) * | 2007-12-13 | 2009-06-18 | Novartis Ag | Organic compounds |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9358352B2 (en) | 2008-06-13 | 2016-06-07 | Mannkind Corporation | Dry powder drug delivery system and methods |
AU2009257311B2 (en) | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
DK2300083T3 (da) | 2008-06-20 | 2013-07-22 | Mannkind Corp | Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg |
TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US20120022127A1 (en) | 2009-04-09 | 2012-01-26 | Thomas Allmendinger | Process for preparing pyrrolidinium salts |
CN107412212B (zh) | 2009-05-29 | 2021-01-22 | 珍珠治疗公司 | 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统 |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
KR101875969B1 (ko) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
GB0921481D0 (en) * | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
CA2785349C (en) * | 2009-12-23 | 2018-07-03 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
KR20120106753A (ko) * | 2009-12-23 | 2012-09-26 | 키에시 파르마슈티시 엣스. 피. 에이. | Copd용 에어로졸 제제 |
EP2515854B1 (en) | 2009-12-23 | 2014-03-19 | Chiesi Farmaceutici S.p.A. | Aerosol formualtion for COPD |
GEP20156311B (en) | 2009-12-23 | 2015-07-10 | Chiesi Farma Spa | Combination therapy for copd |
KR101736529B1 (ko) | 2010-06-14 | 2017-05-17 | 키에시 파르마슈티시 엣스. 피. 에이. | 글리코피로늄 클로라이드의 결정형 |
CN102939281A (zh) * | 2010-06-14 | 2013-02-20 | 奇斯药制品公司 | 格隆氯铵的制备方法 |
CA2807256C (en) * | 2010-08-03 | 2018-08-28 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising a phosphodiesterase inhibitor |
PL2621494T3 (pl) * | 2010-09-30 | 2019-04-30 | Chiesi Farm Spa | Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji |
JO3510B1 (ar) * | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
ES2625858T3 (es) | 2011-04-01 | 2017-07-20 | Mannkind Corporation | Paquete de tipo blíster para cartuchos farmacéuticos |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
CA2841398C (en) | 2011-07-13 | 2020-07-14 | Pharmaxis Ltd | A delivery device comprising a free-standing container |
WO2013008038A2 (en) * | 2011-07-13 | 2013-01-17 | Pharmaxis Ltd | Improvements relating to delivery devices |
KR101995603B1 (ko) | 2011-07-13 | 2019-07-02 | 파맥시스 엘티디 | 전달 장치에 관한 개선 |
JP6018640B2 (ja) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム |
WO2014007772A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
WO2014007767A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose and a ternary component |
US20150202148A1 (en) * | 2012-07-05 | 2015-07-23 | Arven llac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
ES2624294T3 (es) | 2012-07-12 | 2017-07-13 | Mannkind Corporation | Sistemas de suministro de fármacos en polvo seco |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
AU2013100007B4 (en) * | 2013-01-04 | 2013-05-23 | Novartis Ag | System for treating chronic obstructive pulmonary disease |
US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
EP2970149B1 (en) | 2013-03-15 | 2019-08-21 | MannKind Corporation | Microcrystalline diketopiperazine compositions and methods |
CA2905542C (en) | 2013-03-15 | 2022-05-03 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
GB201305825D0 (en) * | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
EP3019153B1 (en) | 2013-07-11 | 2018-09-05 | Chiesi Farmaceutici S.p.A. | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
UA117846C2 (uk) | 2013-12-30 | 2018-10-10 | К'Єзі Фармачеутічі С.П.А. | Стабільна композиція аерозольного розчину під тиском комбінації глікопіроніюброміду та формотеролу |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
HUE049339T2 (hu) | 2014-09-09 | 2020-09-28 | Vectura Ltd | Glikopirrolátot tartalmazó készítmény, eljárás és berendezés |
CN105412049B (zh) * | 2014-09-16 | 2020-01-07 | 四川海思科制药有限公司 | 一种干粉吸入剂用药物组合物及其制备方法 |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
BR112017009315A2 (pt) * | 2014-11-05 | 2017-12-19 | Glenmark Pharmaceuticals Ltd | composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios. |
GB201515310D0 (en) * | 2015-08-27 | 2015-10-14 | Jagotec Ag | Pharmaceutical composition |
US9925168B2 (en) * | 2016-01-22 | 2018-03-27 | Chiesi Farmaceutici S.P.A. | Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation |
TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
US11219602B2 (en) | 2017-03-15 | 2022-01-11 | Vectura Limited | Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate |
ES2882153T3 (es) * | 2017-05-11 | 2021-12-01 | Chiesi Farm Spa | Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico |
MX2019012931A (es) * | 2017-05-11 | 2020-01-20 | Chiesi Farm Spa | Proceso para preparar una formulacion de polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico. |
CN107213141A (zh) * | 2017-06-09 | 2017-09-29 | 中国药科大学 | 用于吸入的药物组合物 |
CN109200034A (zh) * | 2017-06-30 | 2019-01-15 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的组合物及其制备方法 |
WO2020019952A1 (zh) * | 2018-07-26 | 2020-01-30 | 四川海思科制药有限公司 | 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用 |
CN111971034A (zh) * | 2018-07-26 | 2020-11-20 | 四川海思科制药有限公司 | 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用 |
KR20200078162A (ko) | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 흡입 제형용 건조 분말 및 이의 제조방법 |
CN109745565B (zh) * | 2019-01-28 | 2021-05-18 | 上海方予健康医药科技有限公司 | 一种用于吸入的干粉组合物及其制备方法 |
KR20220066906A (ko) * | 2019-09-24 | 2022-05-24 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입용 건조 분말 제제를 위한 신규 담체 입자 |
CN116194087A (zh) * | 2020-01-15 | 2023-05-30 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
DE4425255A1 (de) * | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US6613795B2 (en) | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
DK0937041T3 (da) | 1996-11-11 | 2003-08-11 | Christian R Noe | Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel |
DK1131059T3 (da) | 1998-11-13 | 2003-06-30 | Jago Res Ag | Tørpulver til inhalation |
GB9826783D0 (en) | 1998-12-04 | 1999-01-27 | Scherer Ltd R P | Inhalation powders |
JP2001151673A (ja) * | 1999-09-06 | 2001-06-05 | Nikken Chem Co Ltd | 吸入用粉末製剤の製造方法 |
GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
US7744855B2 (en) | 2000-06-27 | 2010-06-29 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
EP1337240B2 (en) | 2000-11-30 | 2014-09-24 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US6634466B1 (en) * | 2001-12-12 | 2003-10-21 | Master Concepts, Inc. | Brake pedal fastener |
JP2006522634A (ja) | 2003-04-14 | 2006-10-05 | ベクトゥラ・リミテッド | 投与効率を向上させるデバイス及び製薬組成 |
GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
SG146648A1 (en) | 2003-09-15 | 2008-10-30 | Vectura Ltd | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
US20060292081A1 (en) | 2003-09-15 | 2006-12-28 | Vectura Limited | Methods for preparing pharmaceutical compositions |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
GB0324918D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
-
2006
- 2006-06-30 GB GBGB0613161.9A patent/GB0613161D0/en not_active Ceased
-
2007
- 2007-06-28 US US12/305,263 patent/US20090209502A1/en not_active Abandoned
- 2007-06-28 WO PCT/EP2007/005744 patent/WO2008000482A1/en active Application Filing
- 2007-06-28 ES ES07764925T patent/ES2424754T3/es active Active
- 2007-06-28 BR BRPI0713777A patent/BRPI0713777B8/pt active IP Right Grant
- 2007-06-28 PL PL07764925T patent/PL2037879T3/pl unknown
- 2007-06-28 CA CA2655381A patent/CA2655381C/en active Active
- 2007-06-28 CN CN2007800250151A patent/CN101484134B/zh active Active
- 2007-06-28 EP EP07764925.9A patent/EP2037879B1/en not_active Revoked
- 2007-06-28 AU AU2007264000A patent/AU2007264000B2/en active Active
- 2007-06-28 PT PT77649259T patent/PT2037879E/pt unknown
- 2007-06-28 RU RU2009102934/15A patent/RU2453302C2/ru active
- 2007-06-28 KR KR1020087031818A patent/KR101400579B1/ko active IP Right Grant
- 2007-06-28 MX MX2008016356A patent/MX2008016356A/es active IP Right Grant
- 2007-06-28 JP JP2009516996A patent/JP5266213B2/ja active Active
-
2011
- 2011-10-12 US US13/271,689 patent/US20120065174A1/en not_active Abandoned
-
2015
- 2015-04-21 US US14/692,033 patent/US20150224194A1/en not_active Abandoned
- 2015-12-07 US US14/960,472 patent/US10314784B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2008000482A1 (en) | 2008-01-03 |
US20150224194A1 (en) | 2015-08-13 |
KR20090023650A (ko) | 2009-03-05 |
US10314784B2 (en) | 2019-06-11 |
ES2424754T3 (es) | 2013-10-08 |
MX2008016356A (es) | 2009-01-16 |
BRPI0713777A2 (pt) | 2012-10-30 |
JP5266213B2 (ja) | 2013-08-21 |
JP2009541393A (ja) | 2009-11-26 |
PT2037879E (pt) | 2013-08-27 |
US20120065174A1 (en) | 2012-03-15 |
CN101484134B (zh) | 2012-08-08 |
EP2037879B1 (en) | 2013-05-15 |
CA2655381C (en) | 2014-10-21 |
US20090209502A1 (en) | 2009-08-20 |
US20160081934A1 (en) | 2016-03-24 |
BRPI0713777B8 (pt) | 2021-05-25 |
RU2009102934A (ru) | 2010-08-10 |
CA2655381A1 (en) | 2008-01-03 |
KR101400579B1 (ko) | 2014-05-28 |
GB0613161D0 (en) | 2006-08-09 |
EP2037879A1 (en) | 2009-03-25 |
AU2007264000B2 (en) | 2011-06-09 |
CN101484134A (zh) | 2009-07-15 |
RU2453302C2 (ru) | 2012-06-20 |
BRPI0713777B1 (pt) | 2019-08-27 |
AU2007264000A1 (en) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2037879T3 (pl) | Kompozycje soli glikopironiowej do inhalacji | |
ZA200900029B (en) | Improvements relating to biocidal compositions | |
ZA200706345B (en) | Amino-pyridines as inhibitors of ß-secretase | |
IL197869A0 (en) | Compositions of chk1 inhibitors | |
ZA200808253B (en) | Inhibition of alpha-synuclein toxicity | |
GB0621607D0 (en) | Inhibitors of c-Met | |
EP2054056A4 (en) | SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | |
EP2054397A4 (en) | SMALL MOLECULAR HEMERS OF KYNURENINE-3-MONOXYGENASE | |
ZA200905134B (en) | Compositions of stable tiacumicins | |
EP1991200A4 (en) | FLUORCHINOLONZUSAMMENSETZUNGEN | |
IL194494A0 (en) | Thiazolyldihydrocyclopentapyrazoles for use as pi3-kinase inhibitors | |
IL197632A0 (en) | Use of jam-c binding compounds | |
GB0604899D0 (en) | Derivatives of 18-glycyrrhetinic acid | |
IL197235A0 (en) | Therapeutic compositions | |
IL196000A0 (en) | 2-arylindole derivatives as npges-i inhibitors | |
EP2142188A4 (en) | PROCESS FOR SUPPRESSING LTP INHIBITION | |
IL196809A0 (en) | Di-aromatic substituted amides as inhibitors for glyt1 | |
ZA200901641B (en) | Intermediates for preparation of polymeric compositions | |
GB0618703D0 (en) | Synthesis of leikotriene compounds | |
EP2042499A4 (en) | SALTS OF MORPHOLINE COMPOUND | |
HU0600482D0 (en) | Composition of additives | |
GB0700179D0 (en) | Use of epoxidised compounds | |
GB0708221D0 (en) | Corrosion-inhibiting composition | |
SG10201601998PA (en) | Compositions containing lignan-class compounds | |
ZA201003156B (en) | Use of liquefied-gas compositions |